Bolt Biotherapeutics gains on promising data from cancer therapy trial
30/03/2023 13:34
** Drug developer Bolt Biotherapeutics Inc's shares BOLT.O
up 7.8% at $1.4 premarket
** Co said late-Wednesday its experimental cancer therapy,
BDC-1001, showed anti-tumor activity through "multiple" partial
responses and tumor shrinkage in its early-stage dose-escalation
study
** The therapy is being tested in patients with
HER2-expressing solid tumors
** Brokerage H.C. Wainwright says data supports the
selection of a recommended mid-stage development
** Forecasts BDC-1001 launch in 2026 with sales of $11.4
mln, growing to $320.9 mln sales in 2030
** BDC-1001 was well tolerated at all dose levels, both as
monotherapy and in combination with Bristol-Myers Squibb's
BMY.N Opdivo - BOLT
** H.C. Wainwright adds BOLT's clinical supply agreement
with Roche to evaluate BDC-1001 in combination with Roche's
cancer drug Perjeta boosts confidence on therapy's success
** As of last close, BOLT stock marginally down YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))